Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3
InChI
InChIKey=MFFMDFFZMYYVKS-SECBINFHSA-N
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17352677
Curator's Comment: # Merck in 1999
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17580730 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | JANUVIA Approved UseJANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Important Limitations of Use: •JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1.2) •JANUVIA has not been studied in patients with a history of pancreatitis. (1.2, 5.1) 1.1 Monotherapy and Combination Therapy JANUVIA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See Clinical Studies (14). Launch Date1.16095674E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
950 nM |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.52 μM × h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Vomiting... |
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: |
healthy, 18-45 years n = 77 Health Status: healthy Age Group: 18-45 years Sex: M+F Population Size: 77 Sources: |
|
1700 mg single, oral Overdose Dose: 1700 mg Route: oral Route: single Dose: 1700 mg Sources: |
unknown, 86 years |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 12.5% | 200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15, 30 |
no [IC50 >100 uM] | no (co-administration study) Comment: results indicated that sitagliptin was not a time-dependent inhibitor of CYP3A4; sitagliptin did not meaningfully alter the pharmacokinetics of simvastatin. Page: 15, 30 |
||
Page: 6.0 |
no | |||
Page: 15.0 |
no | |||
Page: 6.0 |
no | |||
Page: 9.0 |
no | |||
Page: 15.0 |
no | no (co-administration study) Comment: sitagliptin had no inhibitory effect on the P-gp mediated transport of digoxin, verapmil, ritonavir, adn vinblastine Page: 15.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
inconclusive | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 4, 42 |
yes | |||
Page: 4, 42 |
yes | |||
Page: 4, 15 |
yes | |||
Page: 4, 15 |
yes | yes (co-administration study) Comment: cyclosporin A significantly inhibited P-gp transport of sitagliptin Page: 4, 15 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 22, 23 |
PubMed
Title | Date | PubMed |
---|---|---|
MK-431 (Merck). | 2005 Apr |
|
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. | 2005 Summer |
|
The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation. | 2006 |
|
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | 2006 Dec |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | 2006 Dec |
|
First-in-class diabetes drug approved. | 2006 Dec 1 |
|
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2006 Jul-Aug |
|
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. | 2006 Mar |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | 2006 Nov |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | 2006 Oct |
|
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. | 2006 Sep |
|
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 |
|
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. | 2007 Apr |
|
Characterization of two cyclic metabolites of sitagliptin. | 2007 Apr |
|
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. | 2007 Apr |
|
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. | 2007 Apr 1 |
|
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. | 2007 Aug |
|
Incretins: a new treatment option for type 2 diabetes? | 2007 Feb |
|
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. | 2007 Feb |
|
Finding new treatments for diabetes--how many, how fast... how good? | 2007 Feb 1 |
|
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | 2007 Jan |
|
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. | 2007 Jul |
|
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. | 2007 Jul-Aug |
|
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. | 2007 Jun 15 |
|
New treatments for diabetes. | 2007 May 24 |
|
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | 2007 Sep |
|
Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. | 2008 Feb |
|
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. | 2008 Feb |
|
Dipeptidyl peptidase IV inhibitors and diabetes therapy. | 2008 Jan 1 |
Sample Use Guides
100 mg once daily. It can be taken with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23849976
Curator's Comment: Sitagliptin therapy enhances circulating angiogenic cell numbers, angiogenesis and blood flow in the critical limb ischemia area.
Adipose tissue from adult-male Fischer 344 rats were cultured in endothelial progenitor cell culture medium for 14 d with (25 μmol/L) or without sitagliptin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 22:29:43 UTC 2023
by
admin
on
Thu Jul 06 22:29:43 UTC 2023
|
Record UNII |
QFP0P1DV7Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-VATC |
QA10BD12
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-VATC |
QA10BH51
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
NDF-RT |
N0000175913
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-ATC |
A10BH51
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-ATC |
A10BD07
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
NDF-RT |
N0000175912
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-ATC |
A10BD24
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
LIVERTOX |
NBK548083
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-ATC |
A10BH01
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-VATC |
QA10BD07
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-VATC |
QA10BH01
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
||
|
WHO-ATC |
A10BD12
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
486460-32-6
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
QFP0P1DV7Z
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
100000091875
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
C73838
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
DTXSID70197572
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
8692
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
Sitagliptin
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
7516
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL1422
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
SUB25227
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
4369359
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
C496398
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
593411
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
SITAGLIPTIN
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
6286
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
JK-166
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
DB01261
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
M9960
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
QFP0P1DV7Z
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
2448
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY | |||
|
40237
Created by
admin on Thu Jul 06 22:29:45 UTC 2023 , Edited by admin on Thu Jul 06 22:29:45 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
DOSE |
|
||